Fruquintinib Clinical Trials
26 recruitingDrug
Phase 219Phase 42Phase 32Not Applicable2Phase 12
Showing 1–20 of 26 trials
Recruiting
Phase 2
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
Kahr Bio Australia Pty Ltd90 enrolled16 locationsNCT07235293
Recruiting
Phase 2
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
Minimal Residual DiseaseAdjuvant Chemotherapy
M.D. Anderson Cancer Center20 enrolled1 locationNCT07136077
Recruiting
Phase 3
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
Chipscreen Biosciences, Ltd.430 enrolled1 locationNCT06497985
Recruiting
Phase 2
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
Criterium, Inc.120 enrolled9 locationsNCT06992258
Recruiting
Phase 4
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
Takeda78 enrolled45 locationsNCT06562543
Recruiting
Phase 2
Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer
Gastric Cancer Adenocarcinoma Metastatic
Dai, Guanghai68 enrolled1 locationNCT07392346
Recruiting
Phase 1Phase 2
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
Advanced Solid Tumors
AskGene Pharma, Inc.594 enrolled4 locationsNCT05867420
Recruiting
Phase 2
A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study
Fudan University50 enrolled2 locationsNCT05954429
Recruiting
Phase 2
- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
Metastatic Colorectal Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest140 enrolled23 locationsNCT06856837
Recruiting
Phase 2
Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer
Metastatic Colorectal Adenocarcinoma
Barbara Ann Karmanos Cancer Institute102 enrolled9 locationsNCT07130903
Recruiting
Phase 2Phase 3
Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer
Sun Yat-sen University84 enrolled1 locationNCT06441565
Recruiting
Phase 2
Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients
Fudan University25 enrolled1 locationNCT05771181
Recruiting
Phase 1
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
Colon CancerMetastatic Colon Cancer
Sapience Therapeutics130 enrolled11 locationsNCT05848739
Recruiting
Phase 2
Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer
Gastric Cancer
First Affiliated Hospital of Fujian Medical University40 enrolled1 locationNCT06791083
Recruiting
Phase 2
Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC
FruquintinibS-1Raltitrexed
Meng Qiu66 enrolled2 locationsNCT06427005
Recruiting
Phase 2
A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG
Gastric/Gastroesophageal Junction Adenocarcinoma
Henan Cancer Hospital69 enrolled1 locationNCT06774222
Recruiting
Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma
Gastric Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences60 enrolled1 locationNCT06417892
Recruiting
Phase 2
Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma
Hepatocellular CarcinomaImmune Checkpoint InhibitorsSecond-line Treatment+1 more
Sun Yat-sen University36 enrolled1 locationNCT06446154
Recruiting
Phase 2
Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer
Colorectal Cancer Metastatic
Dai, Guanghai46 enrolled1 locationNCT06685276
Recruiting
Phase 2
Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma
Esophageal Neoplasms
Hebei Medical University Fourth Hospital67 enrolled1 locationNCT06646588